Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine

Kuan, R.; Janssen, Robert S.; Heyward, William L.; Bennett, Sean; Nordyke, Robert J.

doi:10.1016/j.vaccine.2013.05.014

Cited by 37 publications

(39 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For each health state considered in the model (stable disease, progression, and liver transplantation) excluding death, utility coefficients were retrieved and an average value was derived. A summary of the retrieved utilities and related mean values is presented in Appendix Table 1 [29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45] …”

Section: Quality-of-life Estimatesmentioning

confidence: 99%

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

et al. 2017

View full text Add to dashboard Cite

From an Italian health care service perspective, TARE could be a cost-effective strategy in comparison with sorafenib for patients with intermediate or advanced HCC. The results from forthcoming randomized controlled trials comparing TARE with sorafenib will be able to confirm or reject the validity of this preliminary evaluation. In the meantime, decision makers can use these results to control and coordinate the diffusion of the technology.

show abstract

Section: Quality-of-life Estimatesmentioning

confidence: 99%

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Potential side-effects of vaccination were considered to be marginal and therefore neglected in the current study as was also done by other HBV vaccine modellers (e.g. [18][19][20]). …”

Section: Vaccination Program Costsmentioning

confidence: 99%

Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile

Mangen

Stibbe

Urbanus

et al. 2017

Vaccine

View full text Add to dashboard Cite

a b s t r a c tBackground: The aim of this study was to evaluate the cost-effectiveness of the on-going decentralised targeted hepatitis B vaccination program for behavioural high-risk groups operated by regional public health services in the Netherlands since 1-November-2002. Target groups for free vaccination are men having sex with men (MSM), commercial sex workers (CSW) and hard drug users (HDU). Heterosexuals with a high partner change rate (HRP) were included until 1-November-2007. Methods: Based on participant, vaccination and serology data collected up to 31-December-2012, the number of participants and program costs were estimated. Observed anti-HBc prevalence was used to estimate the probability of susceptible individuals per risk-group to become infected with hepatitis B virus (HBV) in their remaining life. We distinguished two time-periods: 2002-2006 and 2007-2012, representing different recruitment strategies and target groups. Correcting for observed vaccination compliance, the number of future HBV-infections avoided was estimated per risk-group. By combining these numbers with estimates of life-years lost, quality-of-life losses and healthcare costs of HBV-infections -as obtained from a Markov model-, the benefit of the program was estimated for each risk-group separately. Results: The overall incremental cost-effectiveness ratio of the program was €30,400/QALY gained, with effects and costs discounted at 1.5% and 4%, respectively. The program was more cost-effective in the first period (€24,200/QALY) than in the second period (€42,400/QALY). In particular, the cost-effectiveness for MSM decreased from €20,700/QALY to €47,700/QALY. Discussion and conclusion: This decentralised targeted HBV-vaccination program is a cost-effective intervention in certain unvaccinated high-risk adults. Saturation within the risk-groups, participation of individuals with less risky behaviour, and increased recruitment investments in the second period made the program less cost-effective over time. The project should therefore discus how to reduce costs per riskgroup, increase effects or when to integrate the vaccination in regular healthcare.

show abstract

“…On the other hand, data on the risk for hepatitis B among adults aged 60 y and over are less robust, so that this group of patients could be vaccinated at the discretion of the treating clinician, only after the assessment of the risk and the likelihood of an adequate immune response to vaccination. 61 Concerning the economic evaluations, while Kuan et al 55 found an acceptable incremental C/E (12.613$/QALY), this did not happen for Hoerger et al 54 As far as concerns the quality of these economic evaluations, using the weighted scale of Drummond, very high scores were found (median 91.5; range: 53-98) with the vast majority of the papers (90.9%) with score over 80 ( Table 2). …”

Section: Sample and Resultsmentioning

confidence: 99%

“…CUA (cost-utility analysis) was considered in 8 studies. 41,42,44,49,52,[54][55][56] The population and the countries considered were different in the studies: 5 analyses were conducted in Europe (Bulgaria, Germany, Ireland and UK), 8 in America (all in the USA), 7 in Asia (China, Iran, South Korea Taiwan, Thailand, Vietnam), 1 in Africa (Mozambique) and 1 in Oceania (Australia).…”

Section: Identification Of Relevant Researchmentioning

confidence: 99%

Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013)

Torre

Mannocci

Saulle

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Aim: To conduct a systematic review of the economic evaluations (EE) of HBV vaccination, taking also into account the studies published in the new millennium. Methods: An extensive scientific literature review was conducted using two electronic medical journal databases: Scopus and PubMed engines for published studies on EE of HBV vaccination. Results: 22 articles were reviewed, 9, 5 and 8 cost-effectiveness, cost-benefit and cost-utility analysis, respectively. Studies were mainly concerning EE of universal vaccination (UV), mostly with regards to low or low-medium income countries. For high income countries, EE were focused on the possible implementation of HBV vaccination in particular settings, such as diabetic, renal and other chronic conditions care, as well as infectious diseasesUV has usually a very good cost-effectiveness ratio (80%), ranging from cost-saving (China) or few Euro per LY/QALY gained (in Thailand, and Vietnam) to 630.00$/ QALY in USA (Asian and Pacific Islands) Moreover, EE of HBV vaccination are favorable in the infectious diseases field as well as for chronic conditions. In relation to diabetes the studies gave controversial results. Conclusion: This systematic review highlighted the importance of introducing HBV vaccination not only for infant UV program but also for other settings in which patients are people affected by communicable and non-communicable diseases.

show abstract

Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine

Cited by 37 publications

References 16 publications

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile

Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013)

Contact Info

Product

Resources

About